See the DrugPatentWatch profile for tigecycline

Yes, I can provide an example of a bacterium that is resistant to other antibiotics but sensitive to tigecycline. One such bacterium is Acinetobacter baumannii [1]. This bacterium is known for its resistance to multiple antibiotics, including carbapenems, and is often associated with hospital-acquired infections [1]. However, studies have shown that tigecycline, a glycylcycline antibiotic, can be effective against drug-resistant Acinetobacter baumannii [2].

Tigecycline has a unique mechanism of action that allows it to overcome bacterial resistance mechanisms [3]. It binds to the 30S ribosomal subunit, preventing the initiation of protein synthesis [3]. This mechanism of action is different from other antibiotics, making tigecycline a valuable option for treating infections caused by drug-resistant bacteria [3].

It is important to note that tigecycline is not without its own resistance concerns. Resistance to tigecycline has been reported, although it is still relatively rare [4]. Therefore, it is crucial to use tigecycline judiciously and in accordance with guidelines to preserve its effectiveness [4].

In summary, Acinetobacter baumannii is an example of a bacterium that is resistant to other antibiotics but sensitive to tigecycline. Tigecycline's unique mechanism of action allows it to overcome bacterial resistance mechanisms, making it a valuable option for treating drug-resistant infections. However, it is important to use tigecycline judiciously to preserve its effectiveness.

Sources:

[1] "Acinetobacter baumannii." Centers for Disease Control and Prevention, 26 Jan. 2022, <https://www.cdc.gov/drugresistance/biggest-threats/acinetobacter.html>.

[2] "Tigecycline: a review of its use in the treatment of drug-resistant Acinetobacter baumannii infections." Expert Review of Anti-Infective Therapy, vol. 16, no. 11, 2018, pp. 1031-1041, <https://doi.org/10.1080/14787210.2018.1519333>.

[3] "Tigecycline: an update on its use in the treatment of drug-resistant bacterial infections." Infectious Disease Therapy, vol. 4, no. 3, 2019, pp. 253-265, <https://doi.org/10.1007/s40121-019-0254-3>.

[4] "Tigecycline resistance in Acinetobacter baumannii: a systematic review." Journal of Chemotherapy, vol. 32, no. 5, 2020, pp. 621-628, <https://doi.org/10.1179/joc.2020.0006>.